Literature DB >> 19252974

Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases.

Leanne M Johnson-Huang1, N Scott McNutt, James G Krueger, Michelle A Lowes.   

Abstract

INTRODUCTION: Inflammatory skin diseases can be examined from many viewpoints. In this review, we consider three distinct cutaneous inflammatory diseases from the point of view of their major lesional dendritic cell (DC) subpopulations. The DC populations considered are Langerhans cells, myeloid DCs, and plasmacytoid DCs (pDCs), with specific attention to the presence and role of the inflammatory counterparts of these cells. From such a "dendritic cell-centric" focus, psoriasis, atopic dermatitis (AD), and cutaneous lupus erythematosus (CLE) are explored. DISCUSSION: In psoriasis, there is a specific population of myeloid "inflammatory" DCs that appears to play an important pathogenic role, while pDCs have been recently implicated in the initiation of psoriatic lesions. In AD, Langerhans cells may be important during initiation, while "inflammatory dendritic epidermal cells" (IDECs) appear to be abundant in lesional epidermis and dermis and contribute to maintenance of AD. These IDECs may actually be analogous to the myeloid inflammatory DCs found in the epidermal and dermal compartments of the skin in psoriasis, although they express distinct surface markers and induce different T cell polarities as a result of different cytokine milieu in which they develop. CLE has been recently characterized as a type I IFN-mediated disease, and pDCs are integral to the pathogenesis of this disease.
CONCLUSION: Thus, these DC subpopulations and their products will be reviewed in the context of these three cutaneous diseases to provide clinico-pathophysiological correlations between the lesional DCs, their products, and the skin diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19252974      PMCID: PMC2874976          DOI: 10.1007/s10875-009-9278-8

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  78 in total

1.  Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells.

Authors:  Eva V Acosta-Rodriguez; Giorgio Napolitani; Antonio Lanzavecchia; Federica Sallusto
Journal:  Nat Immunol       Date:  2007-08-05       Impact factor: 25.606

2.  Efficacy of simvastatin in plaque psoriasis: A pilot study.

Authors:  Ivan Valeryevich Shirinsky; Valery Stepanovich Shirinsky
Journal:  J Am Acad Dermatol       Date:  2007-09       Impact factor: 11.527

3.  The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets.

Authors:  J Wenzel; S Zahn; S Mikus; A Wiechert; T Bieber; T Tüting
Journal:  Br J Dermatol       Date:  2007-08-21       Impact factor: 9.302

4.  Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide.

Authors:  Roberto Lande; Josh Gregorio; Valeria Facchinetti; Bithi Chatterjee; Yi-Hong Wang; Bernhard Homey; Wei Cao; Yui-Hsi Wang; Bing Su; Frank O Nestle; Tomasz Zal; Ira Mellman; Jens-Michael Schröder; Yong-Jun Liu; Michel Gilliet
Journal:  Nature       Date:  2007-09-16       Impact factor: 49.962

5.  Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells.

Authors:  Michelle A Lowes; Toyoko Kikuchi; Judilyn Fuentes-Duculan; Irma Cardinale; Lisa C Zaba; Asifa S Haider; Edward P Bowman; James G Krueger
Journal:  J Invest Dermatol       Date:  2008-01-17       Impact factor: 8.551

Review 6.  TNF-mediated inflammatory disease.

Authors:  J R Bradley
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

Review 7.  Thymic stromal lymphopoietin and OX40 ligand pathway in the initiation of dendritic cell-mediated allergic inflammation.

Authors:  Yong-Jun Liu
Journal:  J Allergy Clin Immunol       Date:  2007-08       Impact factor: 10.793

8.  Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages.

Authors:  Lisa C Zaba; Judilyn Fuentes-Duculan; Ralph M Steinman; James G Krueger; Michelle A Lowes
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

9.  Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis.

Authors:  Francesca Capon; Paola Di Meglio; Joanna Szaub; Natalie J Prescott; Christina Dunster; Laura Baumber; Kirsten Timms; Alexander Gutin; Victor Abkevic; A David Burden; Jerry Lanchbury; Jonathan N Barker; Richard C Trembath; Frank O Nestle
Journal:  Hum Genet       Date:  2007-06-22       Impact factor: 4.132

10.  Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses.

Authors:  Lisa C Zaba; Irma Cardinale; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; Mayte Suárez Fariñas; Judilyn Fuentes-Duculan; Inna Novitskaya; Artemis Khatcherian; Mark J Bluth; Michelle A Lowes; James G Krueger
Journal:  J Exp Med       Date:  2007-11-26       Impact factor: 14.307

View more
  30 in total

1.  IFI27, a novel epidermal growth factor-stabilized protein, is functionally involved in proliferation and cell cycling of human epidermal keratinocytes.

Authors:  W-L Hsieh; Y-H Huang; T-M Wang; Y-C Ming; C-N Tsai; J-H S Pang
Journal:  Cell Prolif       Date:  2015-02-09       Impact factor: 6.831

Review 2.  Psoriasis: what we have learned from mouse models.

Authors:  Erwin F Wagner; Helia B Schonthaler; Juan Guinea-Viniegra; Erwin Tschachler
Journal:  Nat Rev Rheumatol       Date:  2010-09-28       Impact factor: 20.543

3.  Characterization of canine dendritic cells in healthy, atopic, and non-allergic inflamed skin.

Authors:  Meret Elisabeth Ricklin; Petra Roosje; Artur Summerfield
Journal:  J Clin Immunol       Date:  2010-07-31       Impact factor: 8.317

4.  Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris.

Authors:  A Chiricozzi; M Suárez-Fariñas; J Fuentes-Duculan; I Cueto; K Li; S Tian; C Brodmerkel; J G Krueger
Journal:  Br J Dermatol       Date:  2015-11-11       Impact factor: 9.302

5.  IRF4 promotes cutaneous dendritic cell migration to lymph nodes during homeostasis and inflammation.

Authors:  Sandra Bajaña; Kimberly Roach; Sean Turner; Jinny Paul; Susan Kovats
Journal:  J Immunol       Date:  2012-08-29       Impact factor: 5.422

6.  Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production.

Authors:  Hideki Fujita; Kristine E Nograles; Toyoko Kikuchi; Juana Gonzalez; John A Carucci; James G Krueger
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-08       Impact factor: 11.205

Review 7.  The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses.

Authors:  Michelle A Lowes; Chris B Russell; David A Martin; Jennifer E Towne; James G Krueger
Journal:  Trends Immunol       Date:  2013-01-03       Impact factor: 16.687

8.  Monoclonal antibody against macrophage colony-stimulating factor suppresses circulating monocytes and tissue macrophage function but does not alter cell infiltration/activation in cutaneous lesions or clinical outcomes in patients with cutaneous lupus erythematosus.

Authors:  K Masek-Hammerman; E Peeva; A Ahmad; S Menon; M Afsharvand; R Peng Qu; J B Cheng; J Syed; Y Zhan; S P O'Neil; S Pleasic-Williams; L A Cox; D Beidler
Journal:  Clin Exp Immunol       Date:  2015-11-09       Impact factor: 4.330

Review 9.  A modular view of cytokine networks in atopic dermatitis.

Authors:  Irit Carmi-Levy; Bernhard Homey; Vassili Soumelis
Journal:  Clin Rev Allergy Immunol       Date:  2011-12       Impact factor: 8.667

10.  Gene transcription changes in asthmatic chronic rhinosinusitis with nasal polyps and comparison to those in atopic dermatitis.

Authors:  Douglas A Plager; Jane C Kahl; Yan W Asmann; Allan E Nilson; John F Pallanch; Oren Friedman; Hirohito Kita
Journal:  PLoS One       Date:  2010-07-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.